In a report published Friday, Cantor Fitzgerald downgraded its rating on Ligand Pharmaceuticals (NASDAQ: LGND) from Buy to Hold, and lowered its price target from $28.00 to $23.00. Cantor Fitzgerald noted, “After attending a Hepatitis C lecture and speaking with physicians at the New York Society for Gastrointestinal Endoscopy on December 19 we ar